Genelabs Withdraws Prasterone Application In Europe; U.S. Confirmatory Trial Stays On Schedule

The company is seeking a partner for Europe to assist in future regulatory discussions after data were deemed insufficient. An additional U.S. trial confirming prasterone's effects on bone loss is expected to be complete by year-end.